ORDER_66
The Fire Rises 2023
PRPO
Eyeing nbrv at this price
I should have rebrought when it hit $4 yesterday...
fukk!!!
The Official CORMEDIX (CRMD)thread (run up to FDA approval has begun )
- Thread starter Tug life
- Start date
I should have rebrought when it hit $4 yesterday...
fukk!!!
I should have rebrought when it hit $4 yesterday...
Any major news and this stock is hitting 10+ And that’s being very conservative
Edit: 12+ with PR
Last edited:
trust the processit might hit $10 today. I love low float stocks. In the coming weeks I'll start another position on a dip
You got your 9 dip rn
Thinking about liquidating my crmd position... not because it’s a bad company, tug is on point with his DD but approval can be a long long time from now. I can use that money elsewhere and bring back profits during crmd sidewise trading.
I’m currently eyeing RBZ for a QUICK 20ish% return. Might be a pump and dump.
I’m currently eyeing RBZ for a QUICK 20ish% return. Might be a pump and dump.
Last edited:
Tug life
I stay fly like a guillemot
Yahoo is now part of Oath CRMD earnings report May 13 . We should be getting good guidance on where we stand with the FDA
Tug life
I stay fly like a guillemot
Monday is an extremely important day for CRMD investors. We should be getting guidance on the status of Neutrolin with the FDA in the conference call. Behind the scenes they are setting up a team who specialise in FDA regulatory approvals and meetings and nda (new drug application) filings. If they announce they have been allowed to file the nda, the share price will pop and do very well the next couple of months, anything else we continue to fall. The last conference call they said they should have sent all the data to the FDA to be reviewed a couple of weeks from that time. That was almost 3 months ago, they should have already submitted the data and we should be getting an update Monday.
ORDER_66
The Fire Rises 2023
Tug life
I stay fly like a guillemot
May 13 next Mondayyou mean monday coming up next week...
Tug life
I stay fly like a guillemot
Tomorrow Neutrolin study will be presented
Tug life
I stay fly like a guillemot
Great read on today's meeting about Neutrolin.
Study Shows Investigational Solution Reduces Catheter-Related Infections | CRMD Message Board Posts
Investigators present findings at the National Kidney Foundation’s 2019 Spring Clinical Meetings
New York, NY – May 10, 2019 - Results of the LOCK-IT-100 study presented this week at the National Kidney Foundation’s 2019 Spring Clinical Meetings in Boston provide evidence of safety and efficacy for an investigational catheter lock solution that is designed to reduce life-threatening catheter-related bloodstream in patients on dialysis.
Catheter-related infections in hemodialysis remain a significant healthcare issue despite improvements in hand hygiene and catheter care, according to the investigators. Central venous catheters in hemodialysis account for 69 percent of access-related bloodstream infections in hemodialysis although those comprise only 19 percent of prevalent vascular accesses.
“As a practicing nephrologist, I see hemodialysis patients in the clinic every day who are at risk for central venous catheter infections and its complications which can sometimes be fatal,” said investigator Dr. Anil Agarwal of The Ohio State University College of Medicine in Columbus.
The study titled “A Phase III, Prospective, Multicenter, Double-Blind, Randomized, Active Control Study to Demonstrate the Safety and effectiveness of Neutrolin in Preventing Catheter-Related Bloodstream Infections in Subjects Receiving Hemodialysis Therapy as Treatment for End Stage Renal Desease” was presented during the NKF annual conference that draws thousands of kidney health professionals. The solution is used in the catheter to reduce the case of infection.
“The LOCK-IT-100 study impressed me that if Neutrolinâ, the investigational catheter-lock solution, is approved, I will have a new agent with a good safety profile that can help cut the risk of catheter-related bloodstream infections in my patients,” Dr. Agarwal said.
Neutrolinâ, is being developed by CorMedix Inc. The company is working with the U.S. Food and Drug Administration to obtain approval for commercial distribution in the US, according to Dr. Agarwal.
In Boston, thousands of professionals in nephrology gathered to share the latest information, treatment and studies of CKD. Teams presented hundreds of studies during the “poster presentations.”
Study Shows Investigational Solution Reduces Catheter-Related Infections | CRMD Message Board Posts
Investigators present findings at the National Kidney Foundation’s 2019 Spring Clinical Meetings
New York, NY – May 10, 2019 - Results of the LOCK-IT-100 study presented this week at the National Kidney Foundation’s 2019 Spring Clinical Meetings in Boston provide evidence of safety and efficacy for an investigational catheter lock solution that is designed to reduce life-threatening catheter-related bloodstream in patients on dialysis.
Catheter-related infections in hemodialysis remain a significant healthcare issue despite improvements in hand hygiene and catheter care, according to the investigators. Central venous catheters in hemodialysis account for 69 percent of access-related bloodstream infections in hemodialysis although those comprise only 19 percent of prevalent vascular accesses.
“As a practicing nephrologist, I see hemodialysis patients in the clinic every day who are at risk for central venous catheter infections and its complications which can sometimes be fatal,” said investigator Dr. Anil Agarwal of The Ohio State University College of Medicine in Columbus.
The study titled “A Phase III, Prospective, Multicenter, Double-Blind, Randomized, Active Control Study to Demonstrate the Safety and effectiveness of Neutrolin in Preventing Catheter-Related Bloodstream Infections in Subjects Receiving Hemodialysis Therapy as Treatment for End Stage Renal Desease” was presented during the NKF annual conference that draws thousands of kidney health professionals. The solution is used in the catheter to reduce the case of infection.
“The LOCK-IT-100 study impressed me that if Neutrolinâ, the investigational catheter-lock solution, is approved, I will have a new agent with a good safety profile that can help cut the risk of catheter-related bloodstream infections in my patients,” Dr. Agarwal said.
Neutrolinâ, is being developed by CorMedix Inc. The company is working with the U.S. Food and Drug Administration to obtain approval for commercial distribution in the US, according to Dr. Agarwal.
In Boston, thousands of professionals in nephrology gathered to share the latest information, treatment and studies of CKD. Teams presented hundreds of studies during the “poster presentations.”